Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial

Charlotte Andersson; Peter Weeke; Bente Brendorp; Lars Køber; Emil L Fosbøl; Arya M Sharma; Nick Finer; Ian D Caterson; Richard A Rode; Philip T James; Christian Torp-Pedersen; Charlotte Andersson; Peter Weeke; Bente Brendorp; Lars Køber; Emil L Fosbøl; Arya M Sharma; Nick Finer; Ian D Caterson; Richard A Rode; Philip T James; Christian Torp-Pedersen

doi:10.1186/1743-7075-6-42

Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial

Charlotte Andersson, Peter Weeke, Bente Brendorp, Lars Køber, Emil L Fosbøl, Arya M Sharma, Nick Finer, Ian D Caterson, Richard A Rode, Philip T James, Christian Torp-Pedersen, Charlotte Andersson, Peter Weeke, Bente Brendorp, Lars Køber, Emil L Fosbøl, Arya M Sharma, Nick Finer, Ian D Caterson, Richard A RodePhilip T James, Christian Torp-Pedersen

6 Citations (Scopus)

Abstract

ABSTRACT: BACKGROUND AND AIMS: Elevated levels of serum uric acid are associated with an increased risk of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle plus sibutramine) in an overweight and obese cardiovascular high risk population was studied. METHODS AND RESULTS: Data from a four week single-blind lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) study were analyzed. 2584 patients (24%) had diabetes mellitus (DM) only, 1748 (16%) had cardiovascular disease (CVD) only and 6397 (60%) had both DM + CVD. Uric acid concentrations (mean +/- standard deviation) at screening were significantly higher among patients with CVD compared to patients without CVD (p < 0.0001): 369 +/- 86 mumol/L, 374 +/- 98 mumol/L and 342 +/- 87 mumol/L in CVD only, CVD+DM and DM only groups, respectively. During treatment uric acid decreased significantly more in patients without DM (p < 0.0001): -15.0 mumol/L (95% confidence interval -17.7;-12.4), -4.6 mumol/L (-6.2;-3.0), and -6.6 mumol/L (-8.7;-4.5) in CVD only, CVD+DM, and DM only groups, respectively. In patients who failed to lose weight, sibutramine induced lower uric acid levels, but greater weight loss and diabetes were associated with smaller falls in blood uric acid levels; decreasing fasting and urinary glucose concentrations in diabetes were associated with increases in uric acid levels. CONCLUSION: A four week daily intake of sibutramine and life style changes was associated with significant reductions in mean uric acid levels. Changes in renal glucose load in diabetes seem to counteract a potential uricosuric effect of sibutramine. TRIAL REGISTRATION: The trial is registered at ClinicalTrial.gov number: NCT00234832.

Original language	English
Journal	Nutrition & Metabolism
Volume	6
Pages (from-to)	42
ISSN	1743-7075
DOIs	https://doi.org/10.1186/1743-7075-6-42 https://doi.org/10.1186/1743-7075-6-42
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

Andersson, C., Weeke, P., Brendorp, B., Køber, L., Fosbøl, E. L., Sharma, A. M., Finer, N., Caterson, I. D., Rode, R. A., James, P. T., Torp-Pedersen, C., Andersson, C., Weeke, P., Brendorp, B., Køber, L., Fosbøl, E. L., Sharma, A. M., Finer, N., Caterson, I. D., ... Torp-Pedersen, C. (2009). Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutrition & Metabolism, 6, 42. https://doi.org/10.1186/1743-7075-6-42, https://doi.org/10.1186/1743-7075-6-42

Andersson, C, Weeke, P, Brendorp, B, Køber, L, Fosbøl, EL, Sharma, AM, Finer, N, Caterson, ID, Rode, RA, James, PT, Torp-Pedersen, C, Andersson, C, Weeke, P, Brendorp, B, Køber, L, Fosbøl, EL, Sharma, AM, Finer, N, Caterson, ID, Rode, RA, James, PT & Torp-Pedersen, C 2009, 'Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial', Nutrition & Metabolism, vol. 6, pp. 42. https://doi.org/10.1186/1743-7075-6-42, https://doi.org/10.1186/1743-7075-6-42

@article{643a22c0117d11df803f000ea68e967b,

title = "Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial",

abstract = "ABSTRACT: BACKGROUND AND AIMS: Elevated levels of serum uric acid are associated with an increased risk of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle plus sibutramine) in an overweight and obese cardiovascular high risk population was studied. METHODS AND RESULTS: Data from a four week single-blind lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) study were analyzed. 2584 patients (24%) had diabetes mellitus (DM) only, 1748 (16%) had cardiovascular disease (CVD) only and 6397 (60%) had both DM + CVD. Uric acid concentrations (mean +/- standard deviation) at screening were significantly higher among patients with CVD compared to patients without CVD (p < 0.0001): 369 +/- 86 mumol/L, 374 +/- 98 mumol/L and 342 +/- 87 mumol/L in CVD only, CVD+DM and DM only groups, respectively. During treatment uric acid decreased significantly more in patients without DM (p < 0.0001): -15.0 mumol/L (95% confidence interval -17.7;-12.4), -4.6 mumol/L (-6.2;-3.0), and -6.6 mumol/L (-8.7;-4.5) in CVD only, CVD+DM, and DM only groups, respectively. In patients who failed to lose weight, sibutramine induced lower uric acid levels, but greater weight loss and diabetes were associated with smaller falls in blood uric acid levels; decreasing fasting and urinary glucose concentrations in diabetes were associated with increases in uric acid levels. CONCLUSION: A four week daily intake of sibutramine and life style changes was associated with significant reductions in mean uric acid levels. Changes in renal glucose load in diabetes seem to counteract a potential uricosuric effect of sibutramine. TRIAL REGISTRATION: The trial is registered at ClinicalTrial.gov number: NCT00234832.",

author = "Charlotte Andersson and Peter Weeke and Bente Brendorp and Lars K{\o}ber and Fosb{\o}l, {Emil L} and Sharma, {Arya M} and Nick Finer and Caterson, {Ian D} and Rode, {Richard A} and James, {Philip T} and Christian Torp-Pedersen and Charlotte Andersson and Peter Weeke and Bente Brendorp and Lars K{\o}ber and Fosb{\o}l, {Emil L} and Sharma, {Arya M} and Nick Finer and Caterson, {Ian D} and Rode, {Richard A} and James, {Philip T} and Christian Torp-Pedersen",

year = "2009",

doi = "10.1186/1743-7075-6-42",

language = "English",

volume = "6",

pages = "42",

journal = "Nutrition & Metabolism",

issn = "1743-7075",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial

AU - Andersson, Charlotte

AU - Weeke, Peter

AU - Brendorp, Bente

AU - Køber, Lars

AU - Fosbøl, Emil L

AU - Sharma, Arya M

AU - Finer, Nick

AU - Caterson, Ian D

AU - Rode, Richard A

AU - James, Philip T

AU - Torp-Pedersen, Christian

AU - Andersson, Charlotte

AU - Weeke, Peter

AU - Brendorp, Bente

AU - Køber, Lars

AU - Fosbøl, Emil L

AU - Sharma, Arya M

AU - Finer, Nick

AU - Caterson, Ian D

AU - Rode, Richard A

AU - James, Philip T

AU - Torp-Pedersen, Christian

PY - 2009

Y1 - 2009

N2 - ABSTRACT: BACKGROUND AND AIMS: Elevated levels of serum uric acid are associated with an increased risk of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle plus sibutramine) in an overweight and obese cardiovascular high risk population was studied. METHODS AND RESULTS: Data from a four week single-blind lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) study were analyzed. 2584 patients (24%) had diabetes mellitus (DM) only, 1748 (16%) had cardiovascular disease (CVD) only and 6397 (60%) had both DM + CVD. Uric acid concentrations (mean +/- standard deviation) at screening were significantly higher among patients with CVD compared to patients without CVD (p < 0.0001): 369 +/- 86 mumol/L, 374 +/- 98 mumol/L and 342 +/- 87 mumol/L in CVD only, CVD+DM and DM only groups, respectively. During treatment uric acid decreased significantly more in patients without DM (p < 0.0001): -15.0 mumol/L (95% confidence interval -17.7;-12.4), -4.6 mumol/L (-6.2;-3.0), and -6.6 mumol/L (-8.7;-4.5) in CVD only, CVD+DM, and DM only groups, respectively. In patients who failed to lose weight, sibutramine induced lower uric acid levels, but greater weight loss and diabetes were associated with smaller falls in blood uric acid levels; decreasing fasting and urinary glucose concentrations in diabetes were associated with increases in uric acid levels. CONCLUSION: A four week daily intake of sibutramine and life style changes was associated with significant reductions in mean uric acid levels. Changes in renal glucose load in diabetes seem to counteract a potential uricosuric effect of sibutramine. TRIAL REGISTRATION: The trial is registered at ClinicalTrial.gov number: NCT00234832.

AB - ABSTRACT: BACKGROUND AND AIMS: Elevated levels of serum uric acid are associated with an increased risk of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle plus sibutramine) in an overweight and obese cardiovascular high risk population was studied. METHODS AND RESULTS: Data from a four week single-blind lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) study were analyzed. 2584 patients (24%) had diabetes mellitus (DM) only, 1748 (16%) had cardiovascular disease (CVD) only and 6397 (60%) had both DM + CVD. Uric acid concentrations (mean +/- standard deviation) at screening were significantly higher among patients with CVD compared to patients without CVD (p < 0.0001): 369 +/- 86 mumol/L, 374 +/- 98 mumol/L and 342 +/- 87 mumol/L in CVD only, CVD+DM and DM only groups, respectively. During treatment uric acid decreased significantly more in patients without DM (p < 0.0001): -15.0 mumol/L (95% confidence interval -17.7;-12.4), -4.6 mumol/L (-6.2;-3.0), and -6.6 mumol/L (-8.7;-4.5) in CVD only, CVD+DM, and DM only groups, respectively. In patients who failed to lose weight, sibutramine induced lower uric acid levels, but greater weight loss and diabetes were associated with smaller falls in blood uric acid levels; decreasing fasting and urinary glucose concentrations in diabetes were associated with increases in uric acid levels. CONCLUSION: A four week daily intake of sibutramine and life style changes was associated with significant reductions in mean uric acid levels. Changes in renal glucose load in diabetes seem to counteract a potential uricosuric effect of sibutramine. TRIAL REGISTRATION: The trial is registered at ClinicalTrial.gov number: NCT00234832.

U2 - 10.1186/1743-7075-6-42

DO - 10.1186/1743-7075-6-42

M3 - Journal article

C2 - 19828038

SN - 1743-7075

VL - 6

SP - 42

JO - Nutrition & Metabolism

JF - Nutrition & Metabolism

ER -

Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this